2015
Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel Eight-Color Flow Cytometry Approach
CHOVANCOVÁ, Jana, Tomáš BERNARD, Olga STEHLÍKOVÁ, David ŠÁLEK, Andrea JANÍKOVÁ et. al.Basic information
Original name
Detection of Minimal Residual Disease in Mantle Cell Lymphoma. Establishment of Novel Eight-Color Flow Cytometry Approach
Authors
CHOVANCOVÁ, Jana (203 Czech Republic, guarantor, belonging to the institution), Tomáš BERNARD (203 Czech Republic), Olga STEHLÍKOVÁ (203 Czech Republic), David ŠÁLEK (203 Czech Republic), Andrea JANÍKOVÁ (203 Czech Republic, belonging to the institution), Jiří MAYER (203 Czech Republic, belonging to the institution) and Michael DOUBEK (203 Czech Republic, belonging to the institution)
Edition
Cytometry Part B: Clinical Cytometry, Hoboken (USA), WILEY-BLACKWELL, 2015, 1552-4949
Other information
Language
English
Type of outcome
Article in a journal
Field of Study
30200 3.2 Clinical medicine
Country of publisher
United States of America
Confidentiality degree
is not subject to a state or trade secret
References:
Impact factor
Impact factor: 2.822
RIV identification code
RIV/00216224:14740/15:00082240
Organization unit
Central European Institute of Technology
UT WoS
000350302000003
Keywords in English
mantle cell lymphoma;minimal residual disease;flow cytometry
Tags
International impact, Reviewed
Changed: 21/3/2016 16:25, Mgr. Eva Špillingová
Abstract
V originále
Backround: Minimal residual disease (MRD) detection is an essential tool for therapy response assessment in a considerable number of hematooncologic disorders including mantle cell lymphoma (MCL). Flow cytometry (FCM) ranks among the most effective approaches which allow rapid sample processing and compete successfully with highly sensitive molecular methods like polymerase chain reaction (PCR). Since FCM is ordinarily applied to detect MRD in B-lineage diseases like chronic lymphocytic leukemia (CLL), a similar method could be used in MCL. We decided to test our novel 8-color FCM approach in MCL MRD detection. Methods: Employing an 8-color FCM protocol designed by us, the expression of 24 selected surface antigens in a cohort of 30 patients with newly diagnosed leukemic MCL and 20 normal controls were compared to one another to establish markers that can reliably distinguish normal B lymphocytes from the MCL population. The sensitivity of the designed protocol was tested using serial dilution studies. Results: Although MCL presents high immunophenotypic variability the combination of CD20/23/5/19/200/62L/3/45 appears to be very favorable in flow cytometric MRD measurement. Conclusions: Our 8-color FCM protocol could easily detect MRD in MCL patients and reaches a sensitivity of up to 2×10-4. This article is protected by copyright. All rights reserved.
Links
| ED1.1.00/02.0068, research and development project |
| ||
| EE2.3.20.0045, research and development project |
| ||
| MUNI/A/0830/2013, interní kód MU |
| ||
| NT13493, research and development project |
| ||
| 7E13008, research and development project |
|